TFF Pharmaceuticals (NASDAQ:TFFP) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday, BidAskClub reports.
A number of other brokerages have also recently commented on TFFP. Maxim Group reaffirmed a “buy” rating and issued a $18.00 target price on shares of TFF Pharmaceuticals in a report on Wednesday. Zacks Investment Research raised TFF Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, September 9th. Finally, Roth Capital boosted their price objective on TFF Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. TFF Pharmaceuticals has an average rating of “Buy” and an average price target of $16.67.
Shares of NASDAQ:TFFP opened at $15.27 on Thursday. The stock has a market capitalization of $332.32 million and a PE ratio of -4.93. The firm’s 50 day moving average price is $12.10 and its 200-day moving average price is $6.87. TFF Pharmaceuticals has a twelve month low of $3.44 and a twelve month high of $16.26.
TFF Pharmaceuticals (NASDAQ:TFFP) last announced its earnings results on Thursday, August 13th. The company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. Equities analysts forecast that TFF Pharmaceuticals will post -0.81 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of TFF Pharmaceuticals by 77.8% in the first quarter. BlackRock Inc. now owns 22,134 shares of the company’s stock valued at $84,000 after acquiring an additional 9,682 shares in the last quarter. Sigma Planning Corp raised its stake in TFF Pharmaceuticals by 5.1% during the 2nd quarter. Sigma Planning Corp now owns 94,150 shares of the company’s stock valued at $542,000 after purchasing an additional 4,600 shares during the period. Nantahala Capital Management LLC lifted its holdings in TFF Pharmaceuticals by 47.9% in the 2nd quarter. Nantahala Capital Management LLC now owns 856,517 shares of the company’s stock worth $4,934,000 after purchasing an additional 277,300 shares in the last quarter. Finally, Gagnon Securities LLC bought a new position in TFF Pharmaceuticals in the 2nd quarter worth approximately $1,268,000. 8.97% of the stock is currently owned by institutional investors and hedge funds.
TFF Pharmaceuticals Company Profile
TFF Pharmaceuticals, Inc, an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
Read More: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.